According to the Zhitong Finance App, Fuxiang Co., Ltd. (300497.SZ) released a performance forecast for the first three quarters of 2026. Net profit attributable to shareholders of listed companies for the first three quarters is expected to be 350 million yuan to 430 million yuan, turning a year-on-year loss into a profit. The sales volume and price of the company's new energy lithium battery electrolyte additive products increased sharply in the first three quarters, driving a sharp increase in the company's performance and turning losses into profits. The new energy business has become the core engine of the company's performance growth.
In addition, the company's pharmaceutical manufacturing business is developing steadily, continuing to promote market expansion, cost reduction and efficiency, focusing on the application of key intermediates across fields. The global market share of many leading products has been in the first tier for many years. The commercialization process of the biological manufacturing microbial protein business is accelerating, opening up room for long-term growth. The company's core product, Weiran® protein, was approved by the National Health Commission in November 2025 as a new food ingredient, making it the first filamentary fungal protein approved in China. Up to now, Weiran® Protein has been admitted to nearly 30 countries around the world, including developed countries in Europe, America, and China, marking that product safety and compliance have been recognized by domestic and foreign authorities, laying a solid compliance foundation for Weiran® Protein products to pass through a wider range of global consumer markets.
During the reporting period, the company's B-side and C-side business layout accelerated simultaneously. On the one hand, the construction of the Weiran® protein project with an annual output of 20,000 tons was accelerated, which is expected to be completed by the end of this year, laying the foundation for subsequent large-scale supply; on the other hand, the company has developed nearly 30 independent brands and co-branded products, such as peptide refreshing bubble water, peptide herbal water, coconut peptide water, protein burgers, protein konjac noodles, protein rice, protein sausage, etc. Among them, beef-flavored and chicken-flavored protein burgers developed and produced through the Slovenian subsidiary Maiyi International have successfully entered mainstream European supermarkets for sale through channels such as SPAR. With market access in nearly 30 countries, a clear product matrix, and gradual implementation of domestic and international channels, the business is expected to become a new growth pole for the company's medium- to long-term performance.